NCT04086082Recruiting
Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging
MAGIK: Using Implanted Markers to Determine the Feasibility of Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging: A Phase I Interventional Study of Lung Cancer Radiotherapy
Source: ClinicalTrials.gov · Last updated 20 May 2026
Brief summary (registry, in English)
This trial will investigate the feasibility of the Markerless Tumour Tracking technology.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 6 May 2019
- Start date
- 24 May 2023
- Primary completion date
- Dec 2028
- Lead sponsor
- University of Sydney
- Diseases
- Lung cancer
- NCT number
- NCT04086082
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 24 May 2023 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous high-dose thoracic radiotherapy.
- Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently with treatment. Hormonal manipulation agents are allowable (e.g. aromatase inhibitors, selective oestrogen receptor modulators, and gonadotropin releasing hormone receptor modulators).
- Targeted agents (such as sunitinib, bevacizumab and tarceva) within 7 days of commencement of treatment, or concurrently with treatment.
Other
- Patient has low respiratory performance as evaluated by the physicians.
- Less than one fiducial marker implanted in the lung.
- Fiducial markers are too far from the tumour centroid (\>9 cm).
- Women who are pregnant or lactating.
- Unwilling or unable to complete quality of life questionnaires.
Who the study is looking for
- Is willing to comply with all trial procedures and intends to provide written Informed Consent for participation in this trial.
- Patients undergoing external beam radiotherapy.
- Histologically proven Stage I NSCLC or oligometastatic lung metastases (3 or less).
- MRI/4D-CT prior to insertion of fiducial markers.
- Patient must be able to have fiducial markers placed in the lung (if on anticoagulants, must be cleared by LMO or cardiologist).
- ECOG performance status 0-2.
- A maximum of three metastases to the lung from any non-haematological malignancy. Multiple metastases will be treated separately.
- 1 cm ≤ Tumour diameter in any dimension ≤ = 5 cm.
- The distance between the tumour centroid and the top end of the diaphragm is \<=10 cm.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Alfred Health Coordinator of this site? Confirm its status | Melbourne | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.